Successful therapy confirmed for newborns with the fatal metabolic disorder MoCD type A

The drug fosdenopterin/rcPMP considerably improves the chances of survival and developmental progress in infants with molybdenum cofactor deficiency (MoCD type A), a rare and life-threatening genetic condition causing an inborn error in metabolism. This was shown in a clinical study recently…

Click here to view the original article.